Wouldn't the companies' data that's already out there and the companies technology vs their competitor's methods for a disease with very limitied treatment already, as well as no debt, be reason to help the share price move? Not saying your wrong, I would just like to have another person's opinion.
News 
Market Data 
Discover 
